CanBas Co., Ltd. (TYO:4575)
Japan · Delayed Price · Currency is JPY 1,013.00
-22.00 (-2.13%)
Jul 16, 2025, 3:30 PM JST
CanBas Company Description
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients.
It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors.
The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
CanBas Co., Ltd.
| Country | Japan |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Takumi Kawabe |
Contact Details
Address: 2-2-1, Otemachi Numazu, 410-0801 Japan | |
| Phone | 81 55 954 3666 |
| Website | canbas.co.jp |
Stock Details
| Ticker Symbol | 4575 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | JPY |
| ISIN Number | JP3244570002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Takumi Kawabe | Chief Executive Officer |
| Makoto Katozumi | Chief Financial Officer |